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Strengths and limitations of this study
 ► The strengths of the project have been the design 
and delivery of a centralised registry for alpha-1 an-
titrypsin deficiency enabling the whole spectrum of 
the disease to be characterised, especially including 
those with more severe disease who are less able 
to travel long distances to single National Centres 
of Excellence.
 ► Recruitment and data collection were rapid and 94% 
of the target.
 ► The study provided further validation of the speci-
ficity of quantitative analysis of lung density for the 
assessment of emphysema in this ‘rare’ disease.
 ► The limitations of the study included the slight short-
fall in patient recruitment over the 1- year target and 
slightly incomplete postbronchodilator physiological 
data entry.
 ► A reduced number of CT scans were analysed be-
cause of recent routine scans performed under 
different parameters. Although all patients filled in 
one of the health status tools, this was not 100% 
for both.
AbStrACt
Objectives To establish a database network for the study 
of alpha-1 antitrypsin deficiency (AATD) and compare the 
results to CT lung density as the most direct measure of 
emphysema.
Design A central electronic database was established to 
permit the upload of anonymised patient data from remote 
sites. Prospectively collected CT data were recorded onto 
disc, anonymised, analysed at the coordinating centre and 
compared with the clinical features of the disease.
Setting Tertiary referral centres with expertise in the 
management of AATD focused on academic Biomedical 
Research Units and Wellcome Clinical Research Facilities.
Participants Data were collected from 187 patients over 
1 year from eight UK academic sites. This included patient 
demographics, postbronchodilator physiology, health 
status and CT. Analysis was undertaken at the coordinating 
centre in Birmingham.
results Patient recruitment in the 12 months reached 
94% of target (set at 200) covering the whole spectrum of 
the disease from those with normal lung function to very 
severe chronic obstructive lung disease. CT scan suitable 
for analysis was available from 147 (79%) of the patients. 
CT density, analysed as the threshold for the lowest 15% 
of lung voxels, showed statistically significant relationships 
with the objective physiological parameters of lung 
function as determined by spirometric Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) severity staging 
(p<0.001) and carbon monoxide gas transfer (p<0.01). 
Density also correlated with subjective measures of quality 
of life (p=0.02).
Conclusions Establishment of the network for data 
collection and its transfer was highly successful facilitating 
future collaboration for the study of this rare disease and 
its management. CT densitometry correlated well with the 
objective clinical features of the disease supporting its 
role as the specific marker of the associated emphysema 
and its severity. Correlations with subjective measures 
of health, however, were generally weak indicating other 
factors play a role.
IntrODuCtIOn
Alpha-1 antitrypsin deficiency (AATD) affects 
around 1 in 2500 individuals in the UK and 
increases the susceptibility to develop chronic 
obstructive pulmonary disease (COPD) with 
an early- onset emphysema dominant pheno-
type and adult- onset liver cirrhosis. Alpha-1 
antitrypsin (AAT) is the main plasma serine 
proteinase inhibitor and is predominantly 
made and secreted by the liver. It enters the 
tissues by simple diffusion especially in the 
presence of inflammation where it regulates 
the local activity of neutrophil proteinases.1 
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Figure 1 The National Institute for Health Research rare 
diseases alpha-1 antitrypsin deficiency network individual 
centres are shown together with their principal Investigators 
and link to the coordinating centre in Birmingham.
Table 1 Baseline characteristics table
Clinical variable
Number of 
subjects Median (IQR)
Age (years) 187 60.1 (50.9–66.9)
Sex   86M 101F (46%M, 54% F)
Pack years for ex- 
smokers
99 17 (8–27)
FEV1 (L) 185 1.4 (0.9–1.9)
FEV1 per cent predicted 185 51.1 (30.5–67.5)
FVC (L) 185 3.6 (2.9–4.8)
FVC per cent predicted 185 105.7 (88.2–123.4)
FEV1/FVC (%) 185 36.9 (28.5–49.8)
Kco per cent predicted 181 56.3 (46.0–69.6)
RV/TLC (%) 140 41.5 (33.0–52.7)
Voxel index −950 HU (%) 147 24.5 (15.4–35.2)
Perc15 (HU) 147 −965.2 (−974.8 to 
−950.7)
Total CAT score 158 18.9 (12.0–25.0)
Total SGRQ score 158 45.2 (33.3–62.1)
Data are shown as median and interquartile ranges together with 
the number of patients where data were collected. All subjects 
were either never smokers or had ceased at least 1 year before 
the time of assessment. CAT score is only given for those where 
the total SGRQ score was also available.
CAT, COPD assessment tool; FEV1, forced expiratory volume in 1 
s; FVC, forced vital capacity; HU, hounsfield units; Kco, carbon 
monoxide transfer coefficient; RV/TLC, residual volume/total 
lung capacity; SGRQ, St George’s Respiratory Questionnaire.
This is important in delicate tissue structures such as the 
alveolar region of the lung where uncontrolled serine 
proteinases can destroy connective tissues leading to alve-
olar destruction and the development of emphysema.2
The study and treatment of rare diseases present many 
problems including patient identification, referral to 
centres with relevant expertise, consistent demographic 
characterisation and importantly the design and delivery 
of appropriately powered research studies and clinical 
trials. With this in mind, the UK National Institute for 
Health Research (NIHR) commissioned a series of proj-
ects in 2014 to develop networks for the study and deep 
phenotyping of rare diseases with the longer term aim of 
providing a consistent structure to facilitate collaboration 
between groups and with industrial partners for research 
and therapeutic development.
In 1996, the Antitrypsin Deficiency Assessment and 
Programme for Treatment (ADAPT) was established in 
Birmingham as an investigator led, industry and research 
grants funded project in order to study AATD and its 
natural history. The programme depended on referrals, 
mainly from secondary care centres in the UK. Patients 
were invited to visit Birmingham on an annual basis for 
assessment as part of a clinical/research programme 
(Local Research Ethics Committee (LREC) 3359a). 
However, although successfully collating data on over 
1000 deficient patients, those seen may be affected by bias 
due to referral patterns as well as to issues of geography 
and transport difficulties for annual visits. The latter issues 
may be especially relevant for the most severely affected 
patients. The ADAPT cohort may therefore underesti-
mate the true impact, especially of the severe end of the 
disease spectrum. In addition, the evolution of a single 
centre impairs delivery of near patient care, clinical trials 
and iterative thought, which can be handicapped by the 
absence of other local centres of excellence more conve-
nient for patient attendance, management and, espe-
cially, recruitment/participation in research and clinical 
trials.
The current article describes the AATD collabora-
tive network funded by the NIHR to establish a patient 
cohort for rare diseases collated over 1 year in the UK. 
In particular, we wished to recruit patients with a wide 
range of severity, with the most severe being recruited 
to the closest specialist centre to minimise the issue of 
difficulty of travel. In particular, we wished to assess lung 
densitometry as the most direct measure of emphysema 
and physiological impairment and patients perception of 
their health status.
MAterIAlS AnD MethODS
Birmingham acted as the coordinating centre for the 
NIHR Rare Diseases Translational Research Collabora-
tion in AATD. Links were made with academic biomedical 
research units where a specialist with expertise in clinical 
trials and interest in AATD had been identified. The 
network had an initial target of 200 patients with AATD 
and the PiZZ genotype recruited from Birmingham, 
Nottingham, London Brompton, London University 
College London/Royal Free Hospital, Cambridge, 
Southampton and Leicester (see figure 1). The aim 
was to recruit 100 patients from Birmingham with mild 
and moderate disease and 100 patients with severe and 
very severe disease (as defined by the forced expiratory 
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Figure 2 Scatter plots of the relation between lung function and CT densitometry analysis. Each point represents data from a 
single patient. The correlation coefficient (r) is given for each analysis using the two best- recognised parameters for emphysema 
on CT scan. KCO, carbon monoxide transfer coefficient; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s.
volume in 1 s (FEV1)) from the other centres such that 
the distance these patients had to travel was less than 
attending a single central facility. A standard protocol was 
provided to all centres based on that used in all previous 
publications from the core Birmingham centre and 
consisted of general demographic data required for, in 
depth, patient characterisation (the lung function equip-
ment used for the study varied between centres and is 
summarised for each site in the online supplement). This 
characterisation would also provide the basis of patient 
identification for inclusion in subsequent clinical trials 
using national standard operating procedures for lung 
function and specific parameters for CT acquisition.
Patients were recruited sequentially from the indi-
vidual centre clinics according to the spirometric criteria 
outlined above.
All subjects underwent full clinical examination were 
scheduled to undergo full postbronchodilator lung func-
tion testing (according to the Association of Respira-
tory Technology/British Thoracic Society guidelines for 
quality control) including spirometry gas transfer and 
lung volumes, determination of current health status 
using well- established tools (St George’s Respiratory 
Questionnaire (SGRQ) and the COPD assessment tool 
(CAT)). Where routine high resolution CT had not been 
undertaken within the previous 2 years, a scan on full 
inspiration was taken using the following fixed criteria: 
subjects were scanned by spiral multislice CT of the chest 
in the supine position within 4 hours of administration of 
a short- acting bronchodilator. A low radiation dose (140 
kVp) was used, the slice thickness was 5 mm and incre-
ments of 2.5 mm, and a soft reconstruction algorithm 
(B30f) was applied. The anonymised data were subse-
quently transferred to Birmingham on disc for quantita-
tive analysis using Pulmo- CMS (Medis Medical Imaging, 
Leiden, The Netherlands courtesy of Berend Stoel). 
Measurements for voxel index (% voxels less dense than 
−950 HU) and Perc15 (density threshold of the lowest 
15% of the voxels) were assessed for the whole lung such 
that greater voxel index or lower Perc (PD)15 indicated a 
greater amount of emphysema.
Patient and public involvement
The project was approved by five patients who completed 
a traffic light system research proposal review form to give 
their opinion on the research project and the significance 
of its impact on clinical practice. A further patient repre-
sentative was a formal member of the steering committee. 
The information will be part of future presentation to the 
patient group and summarised for dissemination in their 
annual newsletter once accepted for publication. Results 
will also be presented at international speciality meetings. 
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Table 2 Multivariate linear regression models between CT 
density and lung function
CT 
density
Lung 
function 
parameter
Unstandardised 
coefficient SE
PD15 FEV1pp 0.63 0.1 (p<0.001)
FEV1/FVC 
(%)
0.94 0.1 (p<0.001)
Kcopp 0.55 0.1 (p<0.001)
Voxel 
index (%)
FEV1pp −0.48 0.1 (p<0.001)
FEV1/FVC 
(%)
−0.67 0.1 (p<0.001)
Kcopp −0.5 0.8 (p<0.001)
Data are shown for the regression analysis of both CT parameters 
and baseline lung function. ‘pp’ is the per cent predicted.
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
Figure 3 Box plots of CT parameters by GOLD stage. Data 
are shown as box plot of IQR with median value indicated 
by the solid line, whiskers indicate 95% data range and 
outliers are indicated by open circles for each GOLD stage of 
severity. LAA, low area of attenuation.
This project represented a first step towards achieving the 
long- term aims expressed by patients as part of the Euro-
pean Lung Foundation survey of AATD.
Statistical analysis
Baseline characteristics are presented as median and IQR. 
The Pearson’s or Spearman rank correlation coefficient 
between CT density and lung function was calculated. 
Analysis of variance or Kruskall- Wallis was used to assess 
differences between grouped data. Normality of the data 
was tested using the Shapiro- Wilk test, and the level of 
significance was conventionally determined at p<0.05.
reSultS
baseline characteristics
There were 187 patients recruited to the study across the 
eight sites within the 1- year recruitment time. Of these, 
84 with severe and very severe COPD were recruited from 
the satellite sites and 94 mild and moderate disease (as 
well as 9 local patients with very severe disease) were 
recruited by Birmingham. Confirmed post bronchodi-
lator spirometry was available for 185 patients and carbon 
monoxide gas transfer (single breath) for 181. Quantita-
tive CT scan was obtained for 147 patients and all patients 
completed quality of life (QoL) metrics (SGRQ and/or 
CAT) although only 158 patients completed both.
The baseline characteristics are summarised in table 1. 
Data are presented as median and IQR to characterise the 
spread of patients studied. The median age was 60 years 
and the median postbronchodilator FEV1 for the cohort 
was 51.1% predicted for age, sex, height and ethnicity.3 
Of these, 44 (24%) patients (recruited from the periph-
eral sites) were graded as Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) stage 4 at the time 
of study.4 Nine patients with AATD (5%) had an FEV1/
forced vital capacity (FVC) >0.7. The median CAT score 
for the whole group was 18.9 (12.0–25.0) and the median 
total SGRQ score was 45.2 (33.3–62.1).
Smoking history information was available for 178 
patients. Seventy- nine were lifelong never smokers but 
all patients with a smoking history had ceased for more 
than 12 months at the time of recruitment. The median 
smoking history for the ex- smokers (n=99) was 17 pack 
years (IQR 8–27). None of the patients was receiving 
AAT augmentation therapy as it remains unavailable for 
management of emphysema in the UK.
Cross-sectional correlations
Lung function and CT densitometry
The relationship between CT density and lung function 
is shown in figure 2. There were significant correlations 
between both lung density parameters and the physi-
ological parameters shown (p<0.001 all comparisons). 
Significant differences were also seen for CT density 
measurements as both the voxel index (which quantifies 
the proportion of low- density voxels below −950 HU) 
and PD15 (which quantifies the threshold below which 
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Figure 4 Quality of life parameters determined by 
GOLD stage. Data are shown as box plot of IQR with 
horizontal median line, whiskers indicate 95% data range 
and outliers are shown as open circles. Patients with no 
airflow obstruction are shown as a separate group. CAT, 
COPD assessment tool; SGRQ, St George’s Respiratory 
Questionnaire.
Table 3 Quality of life data across each GOLD stage4
GOLD stage Patient number CAT median (IQR) Patient number SGRQ median (IQR)
FEV1/FVC>0.7 9 12 (6–21) 9 27.1 (9.7–48.0)
1 13 15 (9–21) 12 33.4 (19.3–35.7)
2 63 16 (12–21) 63 41.5 (30.9–55.4)
3 39 19 (11–25) 39 48.8 (36.5–67.3)
4 53 20 (13.5–27) 33 62.0 (36.5–67.3)
The number of patients for each Global Strategy for Obstructive Lung Disease (GOLD) stage is shown together with the median and IQR data 
for the CAT and SGRQ total score.
CAT, COPD assessment tool; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SGRQ, St George’s Respiratory Questionnaire.
15% of the overall voxels are sited), between each of the 
GOLD severity stages (p<0.001) (figure 3). There was no 
correlation between residual volume/total lung capacity 
(RV/TLC) and any of the densitometry parameters.
Following adjustment of all these relationships for age, 
sex and pack years, the relationship between density as 
measured by PD15 and voxel index remained significant 
(p<0.001) with no evidence of collinearity (see table 2).
QoL measures and lung function
Within the cohort, the CAT test scores ranged between 
1 and 39/40 (median=18.9; IQR 12–25) and related 
to disease severity as defined by the GOLD stage and 
summarised in figure 4 (p<0.0001). The median SGRQ 
was 45.2 (33.3–62.1) and also related to the GOLD stage 
(p<0.001) shown in figure 4 (p<0.001). The median 
and IQR for CAT and SGRQ in each GOLD stage are 
summarised in table 3.
There were significant correlations (online supplemen-
tary table 1) between both QoL measures and spirom-
etry, as measured by FEV1 (per cent predicted), FVC (per 
cent predicted), FEV1/FVC (%) and with gas transfer 
coefficient, Kco (per cent predicted) and gas trapping 
as measured by RV/TLC % (p<0.01 all comparisons). 
Online supplementary figures 1 and 2 summarise the 
correlations for SGRQ and CAT with FEV1 (% predicted).
QoL measures and CT density
Both QoL measures were worse the greater the emphy-
sema as quantified by the lung density. There was a signif-
icant relationship between voxel index and CAT (r=0.18, 
p=0.019) and a weaker relationship with PD15 (r=0.15, 
p=0.043) (figure 5). Total SGRQ correlated significantly 
with both measures of CT density, although again the 
relationship was weak (r2 <0.1) (see figure 5).
DISCuSSIOn
The current paper reports demographic data collated 
from a unique NIHR funded project to establish collab-
orative cohorts of patients with rare diseases focused on 
academic Biomedical Research Units and Wellcome Clin-
ical Research Facilities. The main purpose of this project 
was to recruit 200 patients (none of whom were receiving 
augmentation therapy) with AATD (PiZZ genotype) 
to a central database over a 1- year period as a basis for 
ongoing collaborative research. The aim of the collabo-
rative was to recruit and characterise patients with AATD 
in depth across centres with a wide spectrum of severity. 
Importantly we wished to include those with severe and 
very severe disease (GOLD stages 3 and 4) as quantified 
by baseline FEV1 (4) in the satellite centres local to their 
dwelling, who are more likely to refrain from travel to a 
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Figure 5 Scatter plots to show the relation between quality of life and CT analysis. Data are shown for individual patient CAT 
and total SGRQ scores related to emphysema parameters. The significance of the relationships is indicated (p).CAT, COPD 
assessment tool; SGRQ, St George’s Respiratory Questionnaire.
more distant central facility. Of note the data for the very 
severe patients produced similar values and demographic 
relationships to those seen historically in the single centre 
ADAPT programme in Birmingham.
We have confirmed the feasibility of this approach 
with recruitment from multiple academic centres in 
this limited time period reaching 94% of the target. Of 
these 98% had confirmed postbronchodilator spirometry 
(in 2 patients it had not been documented), 92% were 
able to complete gas transfer measurements and 85% 
had both the SGRQ and CAT measurement of health 
status although most patients (95%) had CAT recorded. 
CT scans were a unique feature of the UK patients and 
were performed prospectively at baseline using a fixed 
protocol and copied anonymously on to disc for analysis 
in Birmingham. This resulted in a total of 147 scans avail-
able and suitable for analysis (79% of patients) enabling 
the relationships to clinical parameters to be explored.
The patients showed a wide spectrum of disease 
including 53 patients local to the participating centres 
classified as GOLD stage 4. Health status showed a rela-
tionship to spirometric severity with worsening for each 
stage although (as expected) with a wide range and major 
group overlap as reported from the larger ADAPT data-
base5 and other studies of non- AATD COPD.6 Impor-
tantly, the patients in GOLD stage 4 had a median total 
SGRQ score 62.0 (IQR 36.5–67.3) which was similar to 
that for 51 stage 4 patients recruited previously to the 
ADAPT database (extracted from Stockley et al5) with a 
median value of 59.1 (IQR 51.8–72.0). This suggests that 
our previous data were not influenced by acquisition bias 
as a result of travel to a single centre being influenced by 
distance and/or patient health. In addition, it indicates 
that GOLD stage4 patients can be readily recruited from 
multiple sites for research, audit and appropriate clinical 
trial purposes.
Relationship of lung densitometry (the most direct 
measure of pathological emphysema) to objective param-
eters of lung function was similar to that seen in other 
studies7 8 but better for gas transfer than spirometry 
(consistent with the former being a more direct measure of 
alveolar dysfunction as seen in emphysema) and certainly 
better than the weak relationship to air trapping (RV/
TLC) and the subjective health status measures. COPD, 
even in AATD, is a multifaceted condition although classi-
cally characterised in AATD by the presence of panacinar 
emphysema localised to the lung bases as the dominant 
pathological phenotype. Lung densitometry is the most 
direct measure of this process and its severity is demon-
strated pathologically.9 All other measures are indirect 
surrogate markers of emphysema, and although densi-
tometry in AATD relates to exercise capacity,10 spirom-
etry and gas transfer11 and health status,12 it remains the 
best independent predictor of mortality in this disease.13 
In addition, it is the most sensitive measure of emphy-
sema progression in AATD14 and hence its support as the 
primary outcome in clinical trials enabling such studies 
to be sufficiently powered for such a rare disease. CT has 
not been routinely undertaken as part of management 
of AATD patients largely on the basis of cost and radia-
tion exposure. However, the radiation exposure protocol 
for densitometry is less than that for high- resolution 
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scans and is specific for the pathological phenotype of 
the COPD in AATD (namely the emphysema). Indeed 
the recent European Respiratory Society (ERS) strategy 
document on AATD has confirmed it as part of the assess-
ment for all such patients and that referral to centres with 
a major interest in AATD should be included in patient 
management.15 The relationships of CT densitometry 
to more recognised parameters of COPD severity and 
mortality are no worse and certainly better (specifically 
mortality) than some of the more conventional markers 
of the disease although still only weakly related to the 
subjective interpretation of the patients’ health.
The study was successful in enabling collaboration 
between academic centres by providing recruitment and 
in- depth phenotyping of a group of patients with AATD 
and a wide range of physiological impairment to an agreed 
standard. All subjects also had plasma taken and stored 
for the development and validation of assays to monitor 
serine proteinase footprints16 and other disease- specific 
biomarkers. In addition, the network provides baseline 
cohort data for long- term follow- up and importantly a 
well- characterised patient database for collaboration with 
industry (one of the key aims for the NIHR programme). 
Furthermore, it conforms to the key elements outlined 
by the ERS strategy document for the management of 
AATD15 ; namely, establishment of registries, comprehen-
sive assessment and review by specialists with an interest 
in AATD. It also provides the background for linking with 
the European Union rare diseases collaborative and the 
European Alpha-1 Research Collaboration.17
Nevertheless, the study has some limitations. Several 
of the patients had undergone CT scanning as part of 
their routine clinical assessment prior to the establish-
ment of the collaborative and hence it was not deemed 
ethical to repeat the procedure in the short term for 
densitometry analysis as part of a phenotyping study. 
However, the parameters are set for all future scans in 
this patient population both at baseline and for moni-
toring progressions. The documentation of health status 
was not perfectly consistent although either the SGRQ 
or CAT was performed in all subjects. Only 85% had the 
SGRQ documented, whereas 95% had the CAT docu-
mented, which may reflect the latter’s ease of administra-
tion and practical clinical utility.4 Our analysis reported 
here only included those patients in whom both had been 
measured. Currently, only the SGRQ has been accepted 
as a validated tool for patient- reported outcomes in clin-
ical trials,18 whereas the CAT has become an accepted 
measure in patient management as supported by GOLD4 
and is often also reported in the clinical studies and 
trials. However, such measures of health status are best 
used to indicate a noticeable change from baseline for 
therapies that provide an initial and detectable impacts 
such as bronchodilators and not therapies that modify 
slow progression of chronic diseases such as COPD 
and emphysema.5 Therefore, although densitometry 
relates to both FEV1 and health status (though poorly 
for the latter), evidence of progression and response to 
treatment in AATD should currently depend on CT scans 
as the most direct and sensitive marker of emphysema 
and its progression as confirmed recently in a placebo- 
controlled trial of the benefit of augmentation therapy.19
In summary, the project successfully recruited to 94% 
of target in the 1- year time frame and the majority under-
went deep phenotyping to a set standard for future 
patient care and assessment consistent with the view of 
the ERS strategy document for AATD.15 The collabora-
tion and expertise of participants provide a firm structure 
for future management of AATD in the UK. Importantly, 
it provides validation that previous patient assessment as 
part of the ADAPT programme reflects patients across 
the spectrum of disease severity and not a patient acqui-
sition bias related to distance or travel. Furthermore, it 
demonstrates an intercalated network that can harmo-
nise activity and research outcomes using standard meth-
odologies. These points give reassurance that patient 
monitoring and care can be provided at multiple sites to 
the same standard, factors that are both critical in patient 
convenience and reassurance, as expressed by patients in 
the recent ERS AATD strategy document.15 Importantly, 
it provides validation of CT densitometry for character-
isation of the pathological nature and severity of the 
disease and places this in perspective with other measures 
routinely used for monitoring. Because of its specificity, 
it should become an essential part of AATD assessment.15 
Finally the collaborative provides an essential, ready- made 
resource for the delivery of research, clinical studies and 
trials especially for the pharmaceutical industry and a UK 
resource for patient/specialist research collaboration.
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